On Tuesday, Medtronic announced the potential acquisition of CathWorks in a press release. Medtronic intends to acquire CathWorks for $585 million. CathWorks is a medical device company working to improve the management of coronary artery disease (CAD). CathWorks integrates artificial intelligence (AI) with systems and procedures for treating CAD, such as the fractional flow reserve (FFR)angio System as an alternative to wire-based FFR for the assessment of coronary physiology. “Medtronic is thrilled to move forward with our option to officially acquire CathWorks. Through our co-promotion agreement, we've seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient's journey, from diagnosis to treatment," Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business at Medtronic, during the press release. "This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care." The U.S. Federal Trade Commission has yet to approve the deal. Approval is expected by the end of 2026. Image Credit: piai – stock.adobe.com